Antioxidant and anti-inflammatory agents mitigate pathology in a mouse model of pseudoachondroplasia

Karen L. Posey1,*, Francoise Coughtry1, Alka C. Veerisetty1, Mohammad Hossain1, Joseph L. Alcorn1 and Jacqueline T. Hecht1,2

1Department of Pediatrics, University of Texas Medical School at Houston, Houston, TX, USA and 2Shriners Hospital for Children, Houston, TX, USA

*To whom correspondence should be addressed. Tel: +1 7135005786; Fax: +1 7135005689; Email: karen.posey@uth.tmc.edu

Abstract

Pseudoachondroplasia (PSACH), a severe short-limb dwarfing condition, results from mutations that cause misfolding of the cartilage oligomeric matrix protein (COMP). Accumulated COMP in growth plate chondrocytes activates endoplasmic reticulum stress, leading to inflammation and chondrocyte death. Using a MT-COMP mouse model of PSACH that recapitulates the molecular and clinical PSACH phenotype, we previously reported that oxidative stress and inflammation play important and unappreciated roles in PSACH pathology. In this study, we assessed the ability of antioxidant and anti-inflammatory agents to affect skeletal and cellular pathology in our mouse model of PSACH. Treatment of MT-COMP mice with aspirin or resveratrol from birth to P28 decreased mutant COMP intracellular retention and chondrocyte cell death, and restored chondrocyte proliferation. Inflammatory markers associated with cartilage degradation and eosinophils were present in the joints of untreated juvenile MT-COMP mice, but were undetectable in treated mice. Most importantly, these treatments resulted in significantly increased femur length. This is the first and only therapeutic approach shown to mitigate both the chondrocyte and long-bone pathology of PSACH in a mouse model and suggests that reducing inflammation and oxidative stress early in the disease process may be a novel approach to treat this disorder.

Introduction

Cartilage oligomeric matrix protein (COMP) is a non-collagenous extracellular matrix (ECM) glycoprotein that is most abundant in musculoskeletal tissues (1–3). In the ECM, COMP interacts with other ECM proteins such as collagen type II, collagen type IX, matrix 3 and SPARC (4,5). Functionally, COMP participates in type II collagen fibril assembly, enhances chondrocyte attachment and proliferation (6–10). Mutations that result in misfolding of COMP cause two skeletal dysplasias, pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (MED/EDM1) (11). Clinically, short stature, rhizomelic shortening of the limbs and shortened fingers (brachydactyly) are classic features of PSACH (11,12). Molecularly, PSACH is associated with massive intracellular retention of COMP and other ECM proteins in the endoplasmic reticulum (ER) of growth plate chondrocytes, leading to premature chondrocyte death before complete skeletal maturation (4,13–15). Newborns with PSACH are indistinguishable from unaffected babies; diagnosis is typically made around 2–3 years of age when a waddling gait develops and linear growth slows (11,12). The most debilitating complication is early onset joint pain generally attributed to joint erosion and osteoarthritis (OA) (11,16).

Previously, we developed an inducible MT-COMP mouse as a model of PSACH through chondrocyte-specific expression of the human COMP with a mutation, D469del, which is found in approximately 30% of PSACH cases (17,18). We have shown that critical cellular and clinical features of PSACH are recapitulated when transgenic human MT-COMP is expressed during growth plate development and maturation, allowing for identification of pathological events and characterization of molecular mechanisms that develop early in the pathogenesis of PSACH (19–21). Using transcriptome analysis and immunostaining of...
growth plates, we found that a proapoptotic environment was established early in development, from E15 to P1. After birth, cellular mechanisms that cope with ER stress resulting from misfolded proteins can prevent substantial chondrocyte death until 3 weeks of age, at which time the majority of chondrocytes retain MT-COMP and necroptosis is triggered by persistent ER stress and DNA damage (20).

Under conditions of unremitting ER stress, inflammation and oxidative stress are stimulated which in turn can exacerbate ER stress, thereby stimulating a self-perpetuating pathological loop between ER stress, inflammation and oxidative stress process (22–26). Consistent with this idea, antioxidant therapies have shown improved secretion of the protein and decreased ER stress resulting from misfolded coagulation factor VIII (27). Similarly, non-steroidal anti-inflammatory drugs (NSAIDs) reduce ER stress in a variety of cell types (28–31). In our MT-COMP mouse, we found that intracellular retention of misfolded mutant COMP drives an inflammatory and oxidative stress response, suggesting that oxidative stress and inflammation feedback generates additional ER stress, which leads to more mutant COMP accumulation and the co-retention of other ECM proteins that typically interact with COMP in the matrix (4,5,8). This vicious cycle of ER stress resulting from intracellular retention in MT-COMP growth plate chondrocytes initiates inflammatory responses and production of reactive oxygen species (ROS) that overwhelm the cellular stress coping mechanisms and cause premature chondrocyte death (20). MT-COMP-induced chondrocyte death occurs through caspase-independent necroptosis (20,32). The intracellular retention of MT-COMP increases CHOP and GADD34 expression, which reactivates protein translation exacerbating intracellular retention of MT-COMP (32). Reactive oxygen species are generated by increases in Nox4 and ER receptor stress-inducible, Ero1β (32). Oxidative stress leads to DNA damage as indicated by increased expression of growth arrest and DNA damage (GADD) genes (32). The presence of cleaved apoptosis inducing factor (tAIF) in the absence of activated caspases (3, 8, 9 and 12) indicates that MT-COMP-induced premature chondrocyte death occurs through necroptosis (32).

In our previous work, we showed that interrupting the ER-stress sensing/signaling mechanisms through the loss of CHOP reduces intracellular retention, inflammatory marker expression and premature chondrocyte cell death and partially restores growth plate chondrocyte proliferation (20). Inflammation and oxidative stress in the MT-COMP growth plate coincides with maximal MT-COMP intracellular retention and chondrocyte death, leading us to hypothesize that suppressing inflammation or oxidative stress may extend chondrocyte longevity. To test this hypothesis, we treated MT-COMP mice from birth to P28 with antioxidants or anti-inflammatory agents (aspirin, ibuprofen, resveratrol, grape seed extract (GSE), turmeric, CoQ10) and assessed intracellular retention, chondrocyte death, inflammation markers and femur lengths.

**Results**

MT-COMP growth plate organization is improved by anti-inflammatory and antioxidant treatment

In previous work, we showed that inflammation and oxidative stress play a role in MT-COMP growth plate chondrocyte pathology (20,21). To determine if reducing inflammation and ROS would ameliorate the disruptive effects of mutant COMP expression on growth plate organization, MT-COMP mice were treated with a variety of over-the-counter antioxidant and anti-inflammatory agents and their effects on growth plate assessed. Expression of MT-COMP was induced using DOX from conception to P28. Experimental and control dams and offspring were treated from P0 to P28 with aspirin, ibuprofen, resveratrol, GSE, turmeric or CoQ10 continuously in the drinking water at concentrations shown in Table 1. C57BL/6 mice were used as controls as we had previously shown that expression of wild-type COMP did not affect growth plate chondrocytes, fertility or longevity (19). At P28, hind limbs were collected, the tibial growth plates sectioned and visualized by H&E staining. As seen previously and shown in Figure 1, chondrocyte-specific induction of MT-COMP expression in mice from conception to P28 disrupts the expected organized columnar arrangement of growth plate chondrocytes. The growth plate from mice expressing MT-COMP is more disorganized with fewer chondrocytes organized into columns (Fig. 1H) compared with the highly organized C57BL/6 growth plate (Fig. 1A) (19,20). In contrast, treatment of mice expressing MT-COMP with any of the antioxidant and anti-inflammatory agents in Table 1 improved growth plate organization with varying degrees of efficacy. Compared with untreated mice expressing MT-COMP (Fig. 1H), columnar organization was fully restored with aspirin (Fig. 1I) and GSE treatment (Fig. 1L) and partially restored by treatment with resveratrol (Fig. 1K), turmeric (Fig. 1M) and CoQ10 (Fig. 1N). However, GSE, turmeric and CoQ10 treated control growth plates showed varying degrees of disorganization as compared with untreated controls (Fig. 1A compared with E-G). This suggests that aspirin and resveratrol may be the best agents to improve growth plate organization because they improve organization in the MT-COMP growth plate and do not negatively impact the control growth plate.

**Table 1. Treatment drugs and dosages**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage in drinking water</th>
<th>Source</th>
<th>Equivalent human dosage for 26 kg child</th>
<th>Equivalent human dosage for 70 kg adult</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>0.3 g/l</td>
<td>Sigma, St Louis, MO, USA</td>
<td>64 mg/daily</td>
<td>166 mg/daily</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>0.08 g/l</td>
<td>Sigma, St Louis, MO, USA</td>
<td>17 mg/daily</td>
<td>45 mg/daily</td>
</tr>
<tr>
<td>Resveratrol*</td>
<td>0.25 g/l</td>
<td>Reserveages Organics, Gainesville, FL, USA</td>
<td>53 mg/daily</td>
<td>140 mg/daily</td>
</tr>
<tr>
<td>Turmeric</td>
<td>20 g/l</td>
<td>Planetary Herbs, Soquel, CA, USA</td>
<td>4 g/daily</td>
<td>11 g/daily</td>
</tr>
<tr>
<td>CoQ10</td>
<td>0.001 g/l</td>
<td>Liqsober, Smithtown, NY, USA</td>
<td>0.2 mg/daily</td>
<td>0.6 mg/daily</td>
</tr>
<tr>
<td>GSE</td>
<td>0.666 g/l</td>
<td>Healthy Origins, Pittsburgh, PA, USA</td>
<td>140 mg/daily</td>
<td>370 mg/daily</td>
</tr>
</tbody>
</table>

*Reserveages Organics liquid resveratrol also contains a mixed berry extract which contains 760 oxygen radical absorbance capacity units (ORAC)/ml.
Antioxidant and anti-inflammatory agents reduce intracellular retention of MT-COMP

Intracellular retention of misfolded mutant COMP in the ER of growth plate chondrocytes is a distinctive feature of PSACH, first documented in 1973 (33). To evaluate intracellular retention of human MT-COMP in treated and untreated transgenic mice, we used an antibody that specifically recognizes human COMP and does not cross react with the endogenous mouse COMP. Since non-transgenic control mice do not express human COMP, no intracellular or extracellular MT-COMP was observed (data not shown) (20). MT-COMP intracellular retention was present in untreated MT-COMP chondrocytes throughout the growth plate (Fig. 2A). Administration of aspirin, ibuprofen and resveratrol from P0-P28 dramatically reduced intracellular retention of MT-COMP in growth plate chondrocytes compared with untreated MT-COMP mice (Fig. 2B–D compared with A). GSE, turmeric and CoQ10 treatment decreased intracellular retention of MT-COMP as well, but to a lesser extent than the other drugs treatments (Fig. 2E–G compared with A). Interestingly, some extracellular MT-COMP was observed with resveratrol and turmeric treatments (Fig. 2D and F). Previously, we observed the export of mutant COMP when the protein was expressed in a CHOP null background, suggesting that interrupting CHOP signaling permits the misfolded protein to bypass the ER quality control systems (20). The finding that resveratrol, an antioxidant, can allow some MT-COMP to be exported to the ECM suggests that oxidative stress and ER stress may be closely linked in growth plate chondrocytes expressing high levels of misfolded proteins.

Cell death is decreased in MT-COMP growth plates treated with antioxidant and anti-inflammatories

Intracellular MT-COMP retention is associated with chondrocyte death in our mouse model and chondrocyte death has been reported in human PSACH growth plates (1,19,20). Since intracellular retention of mutant COMP is decreased by antioxidant/anti-inflammatory treatments in MT-COMP growth plates (Fig. 2), we next assessed efficacy of anti-inflammatories and

Figure 1. Treatment with aspirin or antioxidants improves growth plate organization in MT-COMP mice at P28. H & E staining of representative P28 growth plates from control (C57BL/6) and MT-COMP mice treated with aspirin, ibuprofen, resveratrol, GSE, turmeric or CoQ10 from P0 to P28. Representative growth plates are shown from examination of at least 8 mice. Bar = 500 µm.

Figure 2. Intracellular retention of MT-COMP and chondrocyte death were decreased by treatment with aspirin or antioxidants. TUNEL and human COMP immunostaining of P28 growth plates from control (C57BL/6) and MT-COMP mice treated with aspirin, ibuprofen, resveratrol, GSE, turmeric or CoQ10 from P0 to P28. TUNEL staining is present in only the hypertrophic zone of wild-type mice (C57BL/6) (H), in comparison, most chondrocytes are TUNEL positive in the MT-COMP growth plate (O). TUNEL staining is markedly decreased in MT-COMP chondrocytes with aspirin, ibuprofen, resveratrol, GSE, turmeric or CoQ10 treatment (P–U compared with O). Drug therapy does not change TUNEL staining in control chondrocytes (I–N compared with H). Growth plates from at least 8 mice were examined for each treatment. Bar = 100 µm.
antioxidants on chondrocyte death. As expected, few TUNEL positive chondrocytes were observed in control growth plates and the majority of these were restricted to the hypertrophic zone where chondrocyte death normally occurs (Fig. 2H-N). In contrast, there is widespread chondrocyte death in the growth plate at P28 in the untreated growth plate expressing MT-COMP (Fig. 2O). Previously, we showed that over 80% of MT-COMP expressing chondrocytes are TUNEL positive (20). Aspirin, ibuprofen, resveratrol, GSE and CoQ10, and to a lesser extent with turmeric, treatment reduced TUNEL staining in the MT-COMP growth plates (Fig. 2P-U compared with O). Resveratrol, GSE and CoQ10 treatment was associated with the lowest level of TUNEL staining in the MT-COMP mice (Fig. 2R, S and U).

Chondrocyte proliferation is restored in the MT-COMP growth plates treated with aspirin or resveratrol

In our previous work, using proliferating cell nuclear antigen (PCNA) immunostaining, we found that the level of growth plate chondrocyte proliferation was decreased in MT-COMP mice relative to controls (Fig. 3A and B) (20). Additionally, we have reported that the absence of CHOP in mice expressing MT-COMP reduced retention of MT-COMP in the ER and partially restored chondrocyte proliferation (20). Since our current work indicates that antioxidant or anti-inflammatory treatment of mice expressing MT-COMP reduces retention of MT-COMP, we evaluated whether these treatments would prevent the MT-COMP-induced decrease in chondrocyte proliferation. As seen in Figure 3, treatment of mice expressing MT-COMP with resveratrol and aspirin fully restores PCNA immunostaining in the growth plate as compared with levels seen in control growth plates (Fig. 3B compared with C and D). This suggests that suppressing inflammation or oxidative stress not only preserves growth plate chondrocyte viability but also restores some functions such as cell proliferation.

Antioxidant and anti-inflammatory therapies decrease markers of inflammation in MT-COMP growth plate and articular cartilage chondrocytes

Previously, we found that a variety of inflammatory-related proteins [EPX (eosinophil peroxidase), CCR5 (C-C chemokine receptor type 5), IL-16 (interleukin 16), ECF-L (eosinophil chemotactic factor-lymphocyte also known as YM1), IL-18 (interleukin 18), TNFα (tumor necrosis factor alpha) and IL-1 (interleukin 1)] were increased in untreated MT-COMP mouse growth plate (20,21). We next assessed the effect of aspirin and resveratrol treatments on inflammatory markers present in growth plates expressing MT-COMP (21). All of the inflammatory markers evaluated were decreased by resveratrol and aspirin treatments (Figs 4 and 5). As shown in Figure 4, TNFα, IL-1 and oncostatin (OSM) were markedly reduced by aspirin or resveratrol treatment (Fig. 4E-F compared with D; K-L compared with J; Q-R compared with P) and were similar to the untreated and treated controls (Fig. 4A-C, G–I and M–O) but distinct from the marked expression of TNFα, IL-1 and OSM in MT-COMP growth plate (Fig. 4D, J and P). Ibuprofen treated growth plate chondrocytes showed similar results (data not shown). Likewise, EPX, ECF-L and IL-16 showed similar pattern of expression. As shown in Figure 5, all were decreased in the MT-COMP treated growth plate chondrocytes (E and F, K and L, Q and R) compared with the untreated MT-COMP mice (D, J and P) and similar to the controls (A–C, G–I, M–O).

Femur length in MT-COMP mice is increased by antioxidant and anti-inflammatory treatments

In previous work, we demonstrated that MT-COMP reduces the hind limb length by 12% in mice at 1 month of age (20). Since treatment of mice expressing MT-COMP with these antioxidant and anti-inflammatory agents reverses the cellular pathology associated with expression, we used femoral length to determine whether aspirin or resveratrol treatment improved limb growth in the MT-COMP mice. Mice were treated from P0 to P28 with aspirin or resveratrol and then femurs were measured on microCT images. As shown in Figure 6, the femurs of the MT-COMP mice were shorter than the control femurs consistent with our previous findings (20). Importantly, treatment with resveratrol or aspirin significantly increased femoral length and partially rescues the long-bone phenotype. The treated femur lengths (11.0 ± 0.50 mm aspirin and 10.9 ± 0.47 mm resveratrol) were between those of the control (11.4 ± 0.37 mm) and untreated MT-COMP (10.4 ± 0.25 mm) mice (Fig. 6).

Discussion

We generated the inducible MT-COMP mouse to study the pathologic processes in chondrocytes resulting from mutations in COMP. Using a phenotype-driven approach, we found that
Figure 4. Aspirin or resveratrol treatments decrease expression of cartilage degradation inflammation markers in MT-COMP growth plate chondrocytes. Immunostaining of P28 growth plates from control (C57BL/6) and MT-COMP mice treated with either aspirin or resveratrol from P0 to P28. TNF, IL-1 and OSM immunostaining is shown for control mice (A–C, G–I, M–O) and for MT-COMP mice (D–F, J–L, P–R). Growth plates from at least 8 mice were examined for each treatment. Bar = 100 µm.
Figure 5. Aspirin or resveratrol treatment decreased expression of eosinophil-associated inflammation markers in MT-COMP growth plate chondrocytes. Immunostaining of P28 growth plates from control and MT-COMP mice treated with either aspirin or resveratrol from P0 to P28. EPX, ECF-L and IL16 immunostaining is shown for control mice (A–C, G–I, M–O) and for MT-COMP mice (D–F, J–L, P–R). Growth plates from at least 8 mice were examined for each treatment. Bar = 100 µm.
genes involved in 372 short stature disorders (34). However, ap-
mutations that cause skeletal dysplasias with more than 140
was known about the underlying molecular defects. More recent-
tions have been available for skeletal dysplasias because little

Figure 6. Femur length increased in aspirin or resveratrol treated MT-COMP mice. Femurs were collected at P28 from control (C57BL/6) and MT-COMP after aspirin or
resveratrol treatments from P0–P28. Measurements were obtained as described in the
methods. Both aspirin and resveratrol treatments resulted in significantly increased femoral lengths: C57 = C57BL/6, MT = MT-COMP, Asp = aspirin and
Res = resveratrol. C57BL/6 N = 10, MT-COMP N = 10, MT-COMP aspirin treated
N = 5 and MT-COMP resveratrol treated N = 5. ***P < 0.0005, *P > 0.05.
misfolded retained mutant COMP activates ER stress through
CHOP signaling, resulting in inflammation and oxidative stress
(20). This was an unappreciated consequence of mutant COMP
expression, but importantly led to identification of potential anti-
oxidant and anti-inflammatory therapeutic approaches. Using,
the MT-COMP mouse, we assessed aspirin, ibuprofen, resveratrol,
GSE, turmeric and CoQ10, all readily available over-the-counter
antioxidant and anti-inflammatory therapeutics for the ability
to dampen or prevent the PSACH clinical and chondrocyte phe-
notypes in mice expressing MT-COMP. These agents were se-
lected based upon a long history of safe usage in humans and
their ability to reduce cellular stress, which we have shown to
be a hallmark of PSACH chondrocytes expressing mutant COMP
(19–21). Remarkably, these therapies produced significant ameli-
oration of the short-limb phenotype and resolution of the
chondrocyte-specific pathology.

We found by 1 month of age that all of these therapeutic
agents reduced intracellular accumulation of COMP, inflamma-
tion markers and chondrocyte death throughout the MT-COMP
growth plate. However, resveratrol and aspirin were most effect-
ive at reducing the pathology and thus we focused our studies on
these agents. The most important finding and the gold standard
resulting from treatment was rescue of limb growth by 51–58%
compared with the untreated MT-COMP mouse (Fig. 6). This
is the first report of a therapy that not only suppresses the mutant
COMP pathology in growth plate chondrocyte but also translates
into an increase in murine limb length. This sets the stage for
development of therapies for PSACH, which were identified
using chondrocyte-specific phenotype-driven therapeutic
discovery (20).

Until recently, only symptomatic treatments and/or interven-
tions have been available for skeletal dysplasias because little
was known about the underlying molecular defects. More recent-
ly, researchers have had great success in delineating the genetic
mutations that cause skeletal dysplasias with more than 140
genes involved in 372 short stature disorders (34). However, ap-
proaches to treat these disorders have been limited by the lack
of animal models to delineate the molecular and cellular path-
ologies and to test therapeutics. To circumvent this problem in
PSACH, we generated the MT-COMP mouse with the D469del mu-
tation [the most common mutation that we found accounts for
30% of cases (17,18,35)] and demonstrated that it recapitulates
the clinical and growth plate phenotypes (19,20). Importantly,
we made the novel observation that severe inflammatory and
oxidative responses mediated through CHOP results in chondro-
cyte death and depletion of the growth plate chondrocytes (20).
This observation opened the door for treatment approaches in
the MT-COMP mice using a variety of anti-inflammatory and
antioxidant therapies.

Intracellular accumulation of MT-COMP in the ER of growth
plate chondrocytes is a well-established and characteristic fea-
ture of the PSACH chondrocyte pathology (16,33,36). If inflamma-
tion, oxidative stress and ER stress are interconnected with each
perpetuating the other, then reducing one process should lessen
the others. We tested this hypothesis by administering anti-
oxidants or anti-inflammatory agents and evaluating intracellular
accumulation of MT-COMP. Consistent with this proposed mech-
nanism, aspirin, resveratrol, GSE, turmeric and CoQ10 all reduced
intracellular retention of MT-COMP and inflammatory marker
expression with aspirin and resveratrol having the greatest effect
(Figs 2, 4 and 5). This finding is similar to butylated hydroxyani-
sol (BHA), and antioxidant therapy that improved secretion of
misfolded coagulation factor VIII protein and decreased ER stress
and apoptosis in mice (27). Additionally, several studies have
shown that NSAIDs can reduce ER stress in mice, rats and cell
culture (28–31). For example, in SH-SY5Y neuronal cells in vitro,
thapsigargin/tunicamycin driven ER-stress-induced-apoptosis
was blunted by diclofenac, indomethacin, ibuprofen, aspirin or
ketoprofen, all of which are NSAIDs (28). Our findings and treat-
ment approach may have implications for other ER storage/stress
disorders, such as Alzheimer disease and type II diabetes, which
also result from cross talk between oxidative and inflammation
ER stresses (24,37).

The treatments in this study were chosen based upon toler-
ance/side-effects and their anti-inflammatory and antioxidant
properties. Aspirin and ibuprofen work primarily by inhibiting
cyclooxygenase (COX1 > COX2), which decreases prostaglandin
and thromboxane synthesis, thereby reducing inflammation
http://www.drugbank.ca/drugs/DB01050). Both aspirin and ibu-
profen are NSAIDs (non-steroidal anti-inflammatory drugs) but
aspirin’s irreversible inhibition of COX leads to greater gastro-
intestinal complications. Interestingly, resveratrol, GSE and cur-
cumin (active ingredient in turmeric) reportedly are natural
COX2 inhibitors (38,39). While COX2 inhibition has been reported
to decrease chondrocyte progression to hypertrophy and endo-
chondral ossification (40,41), we found that MT-COMP mice trea-
ted with either aspirin or resveratrol partially recover limb length.
On-going studies will determine whether aspirin treatment/
COX2 inhibition permits only partial limb length rescue or
whether longer treatment (10 weeks) will provide a more com-
plete rescue. Nevertheless, we clearly demonstrate that these
treatments have a positive effect on chondrocyte viability, allow-
ing for at least a partial limb length rescue. This important out-
come would make a profound difference in quality of life issues
for PSACH patients.

Resveratrol is best known for its ability to increase Sirt1 ex-
pression, which has been shown to increase life span of some or-
ganisms in response to caloric restriction (42). We found that
resveratrol modestly increases Sirt1 immunostaining in C57BL/6
but not in MT-COMP growth plates (Supplementary Material,
Fig. S1). Therefore, resveratrol may be acting as both an anti-
oxidant and an anti-inflammatory to dampen the MT-COMP
chondrocyte phenotype through a Sirt1 independent mechanism.
Resveratrol is known to enhance endogenous antioxidant de-
fenses and inhibit phosphodiesterases (PDEs) (43,44). PDE4 is a
direct target of resveratrol and inhibition of PDE4 results in dampening of inflammation through TNFα and interleukins, which we observe. Grape seed extract (proanthocyanidin active compound) has multiple effects on cells including: (1) free radical scavenging, (2) inhibition of COX and 5-LOX that control prostaglandin synthesis and (3) reduction of nitrogen oxide synthase (NOS) activity (38). Tumeric inhibits COX and prevents NF-κB activation (45);(39). CoQ10 is an electron transport carrier used in ATP synthesis, a free radical scavenger and may alter prostaglandin synthesis (http://s406515300.onlinehome.us/coq10morfom.html). There is little information about the mechanism(s) of action of GSE, tumeric and CoQ10, limiting our ability to explain the observed growth plate perturbations.

The most important outcome with respect to PSACH morbidity was increased femoral lengths with both resveratrol and aspirin treatments (Fig. 6). While the modes of action are different for these agents, both interrupt the lethal chondrocyte pathological process induced by mutant COMP retention, thereby improving chondrocyte function and longevity. As seen in Figure 2, apoptosis/cell death in treated murine growth plate chondrocytes is dramatically reduced and chondrocyte proliferation was restored (Fig. 3). This resulted in a significant increase in limb length but did not completely restore full limb length, (Fig. 6) suggesting that there is still compromise of chondrocyte function. Therefore, combining therapies may provide a more efficient rescue and are being tested.

While these therapeutics are readily available and widely used, there are medical concerns especially with long-term aspirin use (46,47). Gastrointestinal irritation and bleeding can occur at any age and aspirin is generally not recommended for children/teenagers with viral illnesses because of the association with Reyes syndrome (http://www.mayoclinic.org/diseases-conditions/reyes-syndrome/basics/definition/con-20020083). To circumvent the risk of Reyes syndrome in children on long-term aspirin therapy, annual flu vaccines and two doses of the varicella (chickenpox) vaccine are given. While aspirin is not administered to children less than 2 years, importantly, most PSACH patients are not diagnosed prior to 2–3 years of age allowing these treatments to fit into the appropriate time frame for therapeutic intervention. Moreover, antioxidants have fewer side-effects and appear to be as effective as aspirin.

Animal studies demonstrate that resveratrol improves metabolic health (48-53). More importantly in the context of this work, resveratrol has been shown to preserve articular cartilage health in a rabbit model of OA (54,55). Consistent with the findings in the OA model, resveratrol decreased inflammation and lengthened femurs in the MT-COMP mouse. There have been several promising clinical trials involving resveratrol (8,56), however the interpretation of these studies is complicated by differences in dosages, delivery method (wine, juice, supplements, etc.) and compound preparation including/excluding synergistic molecules (56). More studies with consistent and rigorous dosing, delivery and preparation of resveratrol are needed to evaluate the potential health benefits of resveratrol in humans.

Inflammatory processes are linked to painful sequelae, and nPSACH, childhood joint pain is a frequent presenting symptom and complaint and is the least understood medical problem with this short stature disorder (11,36,57,58). Our observation of the inflammatory process in growth plate chondrocytes starting at P14 (translates to approximately 4 years in humans) may explain the childhood pain reported in PSACH, which was previously considered to result from abnormal bony/joint architectures. The inflammatory pathologic process in PSACH is an important and novel finding that should be considered in pain management of this condition using appropriate NSAID or antioxidant treatments.

Another potential benefit of NSAID and antioxidant therapies in PSACH may be an amelioration of OA. Osteoarthritis is a common co-morbidity in young adults with PSACH and causes pain and decreased mobility. We demonstrate that NSAID and antioxidant therapies reduce TNFα, IL-1β and OSM markers, all of which are often seen in OA and have been implicated in cartilage degradation in vivo (59–61). To validate that the presence of inflammatory-related proteins is specific to MT-COMP accumulation in the ER and not an immune reaction from human COMP expression in a mouse, growth plates from mice expressing transgenic human wild-type (WT-) COMP were evaluated for the presence of EPX and IL-16. As shown in Supplementary Material, Fig. S2, EPX and IL-16 immunostaining is increased in the MT-COMP mice (B and E) compared with control C57BL/6 (A and D) and WT-COMP (C and F) mice. The inflammatory process therefore is specific to the intracellular retention of MT-COMP and is not a consequence of human COMP expression (Supplementary Material, Fig. S2). For PSACH, it is possible that by decreasing the activity of cytokines associated with OA using antioxidant or anti-inflammatory treatment(s) may decrease joint damage by delaying or diminishing OA (36). This outcome would also dramatically improve the quality of life for individuals with PSACH.

Translation of drug dosages used in MT-COMP mice suggests that aspirin, ibuprofen and resveratrol could be used to treat PSACH. Human equivalent dosage is calculated based on body surface and dosage administered in mg/kg (Human Equivalent Dose = animal dosage mg/kg × animal km/human km) (62). Table 1 lists the pediatric and adult equivalent dosages of the drugs used to treat MT-COMP mice. For juvenile rheumatoid arthritis, pediatric dosages of aspirin 60–90 mg/kg/day are used to initially treat followed by maintenance dosage of 80–100 mg/kg/day (not to exceed 5.4 g/day) for 2- to 11-year olds and 2.4–3.6 g/daily (initially) and maintenance 3.6–5.4 g/daily for children 12 years and over (http://www.drugs.com/dosage/aspirin.html). These dosages are often associated with gastrointestinal complications and are well above the equivalent dosage used to treat MT-COMP mice (Table 1). The pediatric human equivalent of the ibuprofen dosage used in our mice (pediatric 10–30 mg/daily) is below the daily dosages administered to pediatric patients with rheumatoid arthritis (30–50 mg/kg/day). Resveratrol human equivalent dosages are 120–170 mg/daily for adults and 25–75 for children and supplementation of resveratrol to improve cerebral blood flow requires 250–500 mg/daily (http://examine.com/supplements/Resveratrol/). Given that there have been very few side-effects associated with resveratrol supplementation; we expect that 120–170 mg would be easily tolerated. Long-term resveratrol pediatric supplementation studies have not been conducted on a large scale and with little information on pediatric use we are unable to predict tolerance to long-term administration. In addition, human clinical trials will be needed to establish effective dosing parameters.

There have been few treatments for skeletal dysplasias because the growth plate chondrocytes have been considered inaccessible for delivery of drug treatments due to the avascular nature of cartilage. Recently, long-bone growth in an achondroplasia mouse model was rescued by injection of a FGFR3 decoy (63). The mechanism of disease pathology in the achondroplasia and PSACH mice are very different but systemic treatments are able to reach the growth plate chondrocytes and affect a resolution of the disease processes. We now demonstrate that readily available antioxidant and anti-inflammatory therapeutics partially rescue limb growth in the MT-COMP mouse
model of PSACH. Longer administration of antioxidants and anti-inflammatories in MT-COMP mice may generate complete rescue of long-bone growth. This opens the door for innovative approaches to the different types of pathologic processes underlying the skeletal dysplasias and offers potential treatments that may ameliorate the associated morbidities. From a clinical perspective, even partial rescue of limb length and decrease in joint pain would significantly increase functionality for PSACH individuals.

Material and Methods

Generation of transgenic mutant MT-COMP mice

The Animal Welfare Committee at the University of Texas Medical School at Houston approved these studies and all experiments comply with Guide for the Care and Use of Laboratory Animals: Eighth Edition, ISBN-10: 0-309-15396-4. Mutant MT-COMP mice were produced by introducing DNA containing expression cassettes derived from two plasmids, pTRE-MT-COMP (D469del-COMP mutation) and pTET-On-Col II as previously described (19). Mice were administered doxycycline (DOX) (500 ng/ml) through drinking water (with 5% wt/vol sucrose) pre- and postnatally. C57Bl/6 mice were used as controls since the wild-type (WT)-COMP mice showed no phenotypic differences in our previous studies (19).

Drug administration

Each drug was administered from P0 to P28 through drinking water containing DOX at dosages listed in Table 1. Concentrations were used based upon published mouse studies (50,64–70). In our previous studies, we found newborn mice had adverse outcomes to lithium, phenyl butyrate and valproate drugs that reduce ER stress that are well tolerated in adult mice (21). Additionally, prenatal administration of aspirin causes birth defects (71). Therefore, drugs were only administered postnatally.

Immunostaining

Hind limbs from 1-month old MT-COMP and C57Bl/6 control mice were collected and tibial growth plates were analyzed as previously described (19). Briefly, the limbs were fixed in 95% vol/vol ethanol for immunostaining for COMP (Abcam Cambridge, MA ab11056-rat 1:100), eosinophil peroxidase (EPX) (Santa Cruz Biotechnology, Santa Cruz, CA, USA; sc-19147, 1:50), YML/ECF-L (Stem Cell Technologies; 01404, 1:100), interleukin 1α (IL-1α) (Abcam; ab7632, 1:200), interleukin 16 (IL-16) (Santa Cruz Biotechnology; sc-7902, 1:100), oncostatin (OSM) (Santa Cruz Biotechnology; sc-19147, 1:50), and tumor necrosis factor α (TNF-α) (Abcam; ab6671, 1:200), PCNA staining kit (Invitrogen, Carlsbad, CA, USA), and PCNA antisera was used (Abcam, ab9254, 1:200). PCNA staining was visualized by immunofluorescent microscopy. For antibody detection, the Vectastain ABC Kit was used (Vector Laboratories, Burlingame, CA, USA).

Limb length measurements

Hind limbs were obtained from 8 control and 8 MT-COMP mice and the soft tissue was removed. The skeleton was stored in 70% ethanol and then subjected to radiographic examination with an Explore Locus RS microCT (GE Medical Systems, London Ontario). The limbs were attached to a grid to ensure consistency and accuracy of measurements. Measurements were made from end-to-end on femurs using MicroView software (GE Healthcare) as previously described (72). T-test was used to compare the femoral measurements from control and MT-COMP mice limbs.

Supplementary Material

Supplementary Material is available at HMG online.

Acknowledgements

We thank Seunya Vincent and Joanna Espinosa for technical assistance.

Conflict of Interest statement. None declared.

Funding

This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number #1R01AR057117, Shriners Hospital for Children grant to J.T.H. and the Leah Lewis Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References


